What is UroGen Pharma's D&A?

UroGen Pharma (URGN) reported D&A of $75K in Q1 2026.

How has UroGen Pharma's D&A changed year-over-year?

UroGen Pharma's D&A increased by 4.2% year-over-year, from $72K to $75K.

What is the long-term trend for UroGen Pharma's D&A?

Over 4 years (2021 to 2025), UroGen Pharma's D&A has grown at a -18.9% compound annual growth rate (CAGR), from $804K to $347K.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

UroGen Pharma URGN D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.3%

PfizerPFE

$1.61B-0.3%

Johnson & JohnsonJNJ

$2B+13.1%

ImmunityBio, Inc.IBRX

$4.38M+14.4%

Tyra Biosciences, Inc.TYRA

$138K-3.5%

CG OncologyCGON

$841K+3,404%

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's D&A?: UroGen Pharma (URGN) reported D&A of $75K in Q1 2026.
How has UroGen Pharma's D&A changed year-over-year?: UroGen Pharma's D&A increased by 4.2% year-over-year, from $72K to $75K.
What is the long-term trend for UroGen Pharma's D&A?: Over 4 years (2021 to 2025), UroGen Pharma's D&A has grown at a -18.9% compound annual growth rate (CAGR), from $804K to $347K.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.